Elevar Therapeutics announced positive results from a post-hoc analysis of the CARES-310 study, showing that camrelizumab plus rivoceranib provides a clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit for patients with unresectable hepatocellular carcinoma (uHCC), regardless of whether the underlying cause is viral (hepatitis B or C) or non-viral. These findings were presented at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI). The analysis demonstrated improved OS and PFS with the combination therapy compared to sorafenib across all etiology subgroups.
This news is particularly encouraging for uHCC patients, who often face a poor prognosis and limited treatment options. Demonstrating consistent efficacy across different etiologies broadens the potential patient population who could benefit from this combination therapy. This strengthens the argument for camrelizumab plus rivoceranib as a valuable first-line treatment option, potentially offering a new standard of care.
The post-hoc analysis revealed longer median OS with camrelizumab plus rivoceranib compared to sorafenib in patients with non-viral (HR 0.68), HCV (HR 0.37), and HBV (HR 0.70) etiologies. Similarly, median PFS was longer with the combination therapy across all three etiology subgroups (non-viral HR 0.55, HCV HR 0.50, and HBV HR 0.57). The combination therapy’s safety profile remained consistent and manageable across these subgroups. These results build upon previous positive findings from the CARES-310 study, further solidifying the efficacy and safety profile of this combination.
These positive findings support the potential for FDA approval of camrelizumab plus rivoceranib, which is currently under review with a PDUFA date of March 20, 2025. If approved, this combination therapy could significantly improve outcomes for a broader range of uHCC patients and reshape the treatment landscape for this challenging cancer. This could also position Elevar Therapeutics for significant growth and solidify their presence in the oncology market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
